Meta Information
ID:igf-1-lr3
Name:IGF-1 LR3
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-07-02T07:03:07Z
Model
phase-b-newfiles-claude-opus-4.8
Interactions
Target id:
/condition/active-cancer
Target name:
Active cancer / high cancer risk
Severity:
major
Interaction type:
adverse
Nature:
conditional
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
IGF-1 is a potent growth factor; high levels are linked to increased risk and growth of several cancers.
Actionable advice:
IGF-1 LR3 should be avoided with active cancer or high cancer risk.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
high serum concentrations of IGF1 are associated with an increased risk of breast, prostate, colorectal, and lung cancers
Label source:
Fuerstenberger & Senn, Lancet Oncol (2002), PMID 12067807.
Action type:
avoid
Target id:
/class/antidiabetic-medications
Target name:
Insulin / antidiabetic medications
Severity:
major
Interaction type:
adverse
Nature:
relative
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
IGF-1 has insulin-like activity and lowers blood glucose, adding to diabetes medications and risking hypoglycemia.
Actionable advice:
Blood glucose should be monitored closely, as insulin/sulfonylurea doses may need reduction.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
IGF-1 activates insulin/IGF-1 receptors and lowers glucose; additive hypoglycemia with antidiabetics. Established mechanism.
Label source:
Class inference
Action type:
monitor
Target id:
/condition/diabetic-retinopathy
Target name:
Proliferative retinopathy
Severity:
major
Interaction type:
adverse
Nature:
conditional
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
IGF-1 promotes new blood-vessel growth and can worsen proliferative retinopathy.
Actionable advice:
IGF-1 LR3 should be avoided with proliferative diabetic retinopathy or active retinal neovascularization.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
IGF-1 is pro-angiogenic and drives retinal neovascularization. Mechanistic caution.
Label source:
Class inference
Action type:
avoid
Target id:
/condition/fda-compounding-risk
Target name:
Regulatory / unapproved status
Severity:
major
Interaction type:
adverse
Nature:
informational
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
IGF-1 LR3 is a research chemical with no FDA-approved human product; purity, dosing, and safety are unverified.
Actionable advice:
Not FDA-approved for human use; there is no quality assurance for sourced product.
Validation status:
validated_via_regulatory
Evidence tier:
tier_b
Evidence basis:
regulatory_advisory_verbatim
Evidence anchors:
Exact phrase from label:
Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks
Label source:
US FDA compounding advisory. IGF-1 LR3 is an unapproved research peptide.
Action type:
informational_none
Target id:
/class/ghrps-ghrhs
Target name:
GH secretagogues (CJC-1295, ipamorelin, tesamorelin)
Severity:
moderate
Interaction type:
synergistic
Nature:
relative
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Combining IGF-1 with GH-releasing peptides compounds IGF-1 exposure and its risks (glucose, tissue overgrowth, cancer signal).
Actionable advice:
Stacking amplifies IGF-1-related risks; use only under medical supervision with monitoring.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Additive elevation of the GH/IGF-1 axis; compounds IGF-1-related risks. Mechanistic.
Label source:
Class inference
Action type:
monitor